Biomea Fusion highlights initial data from type 1 patients dosed with BMF-219

Biomea Fusion announced initial response data from the first two type 1 diabetes patients treated with BMF-219 in the ongoing Phase II study. Case Study Patient 1 Highlights: A 58-year-old, diagnosed with type 1 diabetes 3 years ago; BMF-219 200 mg once-daily; Week 4: Fasting C-peptide increased by 57% compared to Baseline. During a mixed-meal tolerance test the C-Peptide Index increased by 12%. The C-peptide index is the ratio of serum C-peptide to plasma glucose levels and is used to evaluate beta-cell function; Week 8: Fasting C-peptide increased by 80% compared to Baseline. During a MMTT, C-peptide increased up to 200%. The C-Peptide Index (AUC) increased by 40% compared to Baseline; Data on any changes in daily insulin usage are pending. Case Study Patient 2 Highlights: A 24-year-old, diagnosed with type 1 diabetes 7 years ago; BMF-219 100 mg once-daily; Week 4: Fasting C-peptide increased by 16% compared to Baseline. During a MMTT the C-peptide Index increased by 30%; Patient had a near-normal glucose response during the MMTT without receiving any meal-time insulin; Patient had a reduction in daily insulin usage during the first four weeks of the study.